Oramed boosts stock plan pool, re-elects board

Oramed Pharmaceuticals Inc. reported results of its 2025 annual stockholders meeting held on August 19, 2025.

Accepted by SEC EDGAR 08/21/2025 - 04:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Oramed Pharmaceuticals Inc. reported results of its 2025 annual stockholders meeting held on August 19, 2025. Stockholders approved an amendment to the company’s Amended and Restated 2019 Stock Incentive Plan, increasing the total number of shares of common stock authorized for issuance under the plan by 2,000,000 shares to 9,500,000 shares. This plan is used to grant equity awards to eligible participants, including officers and directors.

All nominated directors were re-elected to serve until the next annual meeting, with each receiving over 12.4 million votes in favor, subject to varying levels of opposition and broker non-votes. Stockholders also ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the company’s independent registered public accounting firm for the 2025 fiscal year.

8-K Event Classification

2 items: 5.02, 5.07

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ORMP stockholders approve regarding the 2019 Stock Incentive Plan?

Stockholders approved an amendment to Oramed Pharmaceuticals Inc.’s Amended and Restated 2019 Stock Incentive Plan to increase the total number of shares of common stock authorized for issuance under the plan by 2,000,000 shares, bringing the aggregate authorization to 9,500,000 shares of common stock.

Who is eligible to receive awards under Oramed (ORMP)’s amended 2019 Stock Incentive Plan?

Under the amended Amended and Restated 2019 Stock Incentive Plan, officers and directors of Oramed Pharmaceuticals Inc., among others, are eligible to receive equity awards, in accordance with the terms and conditions of the plan.

Were Oramed Pharmaceuticals Inc. (ORMP) directors re-elected at the 2025 annual meeting?

Yes. Stockholders re-elected all nominated directors, including Dr. Daniel Aghion, Dr. Miriam Kidron, Nadav Kidron, Dr. Arie Mayer, Yehuda Reznick, Leonard Sank, and Benjamin Shapiro, to serve until the next annual meeting and until their successors are elected and qualified or earlier resignation or removal.

Which auditing firm did ORMP stockholders ratify for the 2025 fiscal year?

Stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as Oramed Pharmaceuticals Inc.’s independent registered public accounting firm for the 2025 fiscal year.

What were the voting results on the amendment to ORMP’s 2019 Stock Incentive Plan?

For the amendment to the Amended and Restated 2019 Stock Incentive Plan, stockholders cast 12,254,197 votes for, 2,106,100 votes against, and 41,652 abstentions, with 6,384,104 broker non-votes.

How did ORMP stockholders vote on ratifying the 2025 independent auditor?

On ratifying Kesselman & Kesselman as independent auditor for 2025, stockholders cast 19,408,725 votes for, 1,359,336 votes against, and 17,992 abstentions, with no broker non-votes.

Where can investors find the full text of ORMP’s incentive plan amendment?

The full text of the amendment to Oramed’s Amended and Restated 2019 Stock Incentive Plan is attached as Appendix A to the company’s Definitive Proxy Statement on Schedule 14A for the 2025 annual meeting, filed on July 16, 2025, and is incorporated by reference.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001176309 0001176309 2025-08-19 2025-08-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 19, 2025

ORAMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

delaware		001-35813		98-0376008
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1185 Avenue of the Americas, Third Floor, New York, New York		10036
(Address of Principal Executive Offices)		(Zip Code)

844-967-2633

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, par value $0.012		ORMP		The Nasdaq Capital Market, Tel Aviv Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 19, 2025, Oramed Pharmaceuticals Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders. At the 2025 Annual Meeting of Stockholders, the Company’s stockholders approved an amendment of the Company’s Amended and Restated 2019 Stock Incentive Plan, as amended (the ” Amended and Restated 2019 Plan”), to increase the aggregate number of shares of common stock, par value $0.012 per share, of the Company (“Common Stock”) authorized for issuance under the Amended and Restated 2019 Plan by 2,000,000 shares of Common Stock to 9,500,000 shares of Common Stock. The amendment to the Amended and Restated 2019 Plan previously had been approved, subject to stockholder approval, by the Company’s Board of Directors.

The Company’s officers and directors are among the persons eligible to receive awards under the Amended and Restated 2019 Plan in accordance with the terms and conditions thereunder. A detailed summary of the amendment to the Amended and Restated 2019 Plan is set forth in the Company’s Definitive Proxy Statement on Schedule 14A for the 2025 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on July 16, 2025 (the “Proxy Statement”) under the caption “Proposal 3: Amendment to Incentive Plan,” which summary is incorporated herein by reference. The full text of the amendment to the Amended and Restated 2019 Plan is attached as Appendix A to the Proxy Statement and incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On August 19, 2025, the Company held its 2025 Annual Meeting of Stockholders. The final voting results at the 2025 Annual Meeting of Stockholders are set forth below.

Proposal No. 1 - Re-election of Directors.

The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows:

Director Name		For				Against				Abstain				Broker Non-Votes
Dr. Daniel Aghion			13,045,437				163,976				1,192,536				6,384,104
Dr. Miriam Kidron			13,031,039				1,333,997				36,913				6,384,104
Nadav Kidron			12,989,716				1,375,014				37,219				6,384,104
Dr. Arie Mayer			12,994,256				215,059				1,192,634				6,384,104
Yehuda Reznick			13,036,242				172,951				1,192,756				6,384,104
Leonard Sank			12,888,223				320,710				1,193,016				6,384,104
Benjamin Shapiro			12,456,964				753,720				1,191,265				6,384,104

1

Proposal No. 2 – Ratification of Independent Registered Public Accounting Firm for the 2025 Fiscal Year.

The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2025 fiscal year. The votes were as follows:

For				Against				Abstain				Broker Non-Votes
	19,408,725				1,359,336				17,992				0

Proposal No. 3 – Approval of an Amendment to the Company’s Amended and Restated 2019 Stock Incentive Plan.

The stockholders approved an amendment to the Company’s Amended and Restated 2019 Stock Incentive Plan. The votes were as follows:

For				Against				Abstain				Broker Non-Votes
	12,254,197				2,106,100				41,652				6,384,104

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ORAMED PHARMACEUTICALS INC.
	By:	/s/ Nadav Kidron
	Name:	Nadav Kidron
	Title:	President and CEO

August 21, 2025

3